Since 1992, there have been more than 190 papers published in peer reviewed medical journals demonstrating EECP® Therapy as a non-invasive, safe, low-cost and highly effective treatment for patients with coronary artery disease. There are 8 randomized controlled trials (RCT) documenting the clinical outcomes and mechanisms of action of EECP Therapy. The most well- known RCTs were the Multicenter Study of EECP (MUST-EECP) in the treatment of patients with angina pectoris and Prospective Evaluation of EECP in Congestive Heart Failure (PEECH™) study. There is also a subgroup study analyzing data from the PEECH™ trial for heart failure patients age 65 or older.
EECP® Clinical Information
EECP® Therapy Clinical Data
External Counterpulsation Therapy Mechanisms of Action
There is evidence demonstrating improved endothelial function via the hemodynamic effects by the increased shear stress acting on the arterial wall, reducing arterial stiffness and providing protective effects against inflammation, inhibiting intimal hyperplasia and the atherosclerotic process.
There is also evidence that ECP therapy triggers a neurohormonal response that induces the production of growth and vasodilatation factors, which together with the increased pressure gradient created across the occlusive site during ECP Therapy, promotes recruitment of new arteries, while dilating and normalizing the function of existing blood vessels. The collaterals bypass stenoses and increase blood flow to ischemic areas of the heart, leading to improved clinical outcomes.